{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:17:32Z","timestamp":1792700252700,"version":"4.5.0"},"reference-count":63,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Serum creatinine\u2013based estimated glomerular filtration rate (eGFRcr) may overestimate the glomerular filtration rate (GFR) in patients with cancer. Cystatin C\u2013based eGFR (eGFRcys) is an alternative marker of GFR.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether the therapeutic drug levels and adverse events (AEs) associated with renally cleared medications were higher in patients with cancer whose eGFRcys was more than 30% lower than their eGFRcr.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study analyzed adult patients with cancer at 2 major academic cancer centers in Boston, Massachusetts. These patients had their creatinine and cystatin C measured on the same day between May 2010 and January 2022. The date of the first simultaneous eGFRcr and eGFRcys measurement was considered to be the baseline date.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n The primary exposure was eGFR discordance, defined as an eGFRcys that was more than 30% lower than the eGFRcr.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was risk of the following medication-related AEs within 90 days of the baseline date: (1) supratherapeutic vancomycin trough level greater than 30 \u03bcg\/mL, (2) trimethoprim-sulfamethoxazole\u2013related hyperkalemia (&amp;gt;5.5 mEq\/L), (3) baclofen toxic effect, and (4) supratherapeutic digoxin level (&amp;gt;2.0 ng\/mL). For the secondary outcome, a multivariable Cox proportional hazards regression model was used to compare 30-day survival of those with vs without eGFR discordance.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1869 adult patients with cancer (mean [SD] age, 66 [14] years; 948 males [51%]) had simultaneous eGFRcys and eGFRcr measurement. There were 543 patients (29%) with an eGFRcys that was more than 30% lower than their eGFRcr. Patients with an eGFRcys that was more than 30% lower than their eGFRcr were more likely to experience medication-related AEs compared with patients with concordant eGFRs (defined as eGFRcys within 30% of eGFRcr), including vancomycin levels greater than 30 \u03bcg\/mL (43 of 179 [24%] vs 7 of 77 [9%];\n P<\/jats:italic>\n \u2009=\u2009.01), trimethoprim-sulfamethoxazole\u2013related hyperkalemia (29 of 129 [22%] vs 11 of 92 [12%];\n P<\/jats:italic>\n \u2009=\u2009.07), baclofen toxic effects (5 of 19 [26%] vs 0 of 11;\n P<\/jats:italic>\n \u2009=\u2009.19), and supratherapeutic digoxin levels (7 of 24 [29%] vs 0 of 10;\n P<\/jats:italic>\n \u2009=\u2009.08). The adjusted odds ratio for vancomycin levels more than 30 \u03bcg\/mL was 2.59 (95% CI, 1.08-7.03;\n P<\/jats:italic>\n \u2009=\u2009.04). Patients with an eGFRcys more than 30% lower than their eGFRcr had an increased 30-day mortality (adjusted hazard ratio, 1.98; 95% CI, 1.26-3.11;\n P<\/jats:italic>\n \u2009=\u2009.003).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n Results of this study suggest that among patients with cancer with simultaneous assessment of eGFRcys and eGFRcr, supratherapeutic drug levels and medication-related AEs occurred more commonly in those with an eGFRcys more than 30% lower than their eGFRcr. Future prospective studies are needed to improve and personalize GFR estimation and medication dosing in patients with cancer.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.21715","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:03:43Z","timestamp":1688555023000},"page":"e2321715","source":"Crossref","is-referenced-by-count":39,"title":["Medication-Related Adverse Events and Discordancies in Cystatin C\u2013Based vs Serum Creatinine\u2013Based Estimated Glomerular Filtration Rate in Patients With Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Paul E.","family":"Hanna","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Strohbehn","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Moreno","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destiny","family":"Harden","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit","family":"Katz-Agranov","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Seethapathy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"issue":"3","key":"zoi230639r1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.ajkd.2014.04.010","article-title":"Measuring GFR: a systematic review.","volume":"64","author":"Soveri","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"zoi230639r2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi230639r3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi230639r4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"19","key":"zoi230639r5","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi230639r6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.7326\/M22-0610","article-title":"Quantifying individual-level inaccuracy in glomerular filtration rate estimation: a cross-sectional study.","volume":"175","author":"Shafi","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi230639r7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi230639r8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/MNH.0000000000000638","article-title":"Cystatin C is ready for clinical use.","volume":"29","author":"Ebert","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"zoi230639r9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2215\/CJN.12791019","article-title":"Kidney disease, race, and GFR estimation.","volume":"15","author":"Levey","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"zoi230639r10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function.","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi230639r11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"zoi230639r12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors.","volume":"101","author":"Costa e Silva","year":"2022","journal-title":"Kidney Int"},{"key":"zoi230639r13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.01.445","article-title":"A prospective cross-sectional study on the performance of the 2021 CKD-EPI equations without race in a multiracial population of adults with solid tumors in Brazil.","author":"Costa E Silva","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"zoi230639r14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1200\/JCO.21.00102","article-title":"Sarcopenia in the older adult with cancer.","volume":"39","author":"Williams","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230639r15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors.","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"zoi230639r16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors.","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"zoi230639r17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.ajkd.2011.05.019","article-title":"Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values.","volume":"58","author":"Inker","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi230639r18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.","volume":"51","author":"Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"zoi230639r19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"zoi230639r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"12","key":"zoi230639r21","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"zoi230639r22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"zoi230639r23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"zoi230639r24","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2147\/IDR","article-title":"Vancomycin trough level and loading dose.","volume":"11","author":"Tuon","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"9","key":"zoi230639r25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ki.2010.35","article-title":"Recent changes in vancomycin use in renal failure.","volume":"77","author":"Vandecasteele","year":"2010","journal-title":"Kidney Int"},{"issue":"1","key":"zoi230639r26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mayocp.2018.08.034","article-title":"Elevated vancomycin trough levels in a tertiary health system: frequency, risk factors, and prognosis.","volume":"94","author":"Zonozi","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"zoi230639r27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/106002809703101108","article-title":"Baclofen toxicity in patients with severely impaired renal function.","volume":"31","author":"Chen","year":"1997","journal-title":"Ann Pharmacother"},{"issue":"5","key":"zoi230639r28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.nefroe.2020.11.003","article-title":"Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function.","volume":"40","author":"Cheong","year":"2020","journal-title":"Nefrologia (Engl Ed)"},{"issue":"12","key":"zoi230639r29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/096032719701601207","article-title":"Digoxin toxicity in chronic renal failure: treatment by multiple dose activated charcoal intestinal dialysis.","volume":"16","author":"Critchley","year":"1997","journal-title":"Hum Exp Toxicol"},{"issue":"6","key":"zoi230639r30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/bcp.1976.3.issue-6","article-title":"Altered distribution of digoxin in renal failure\u2014a cause of digoxin toxicity?","volume":"3","author":"Aronson","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"zoi230639r31","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1111\/bcp.v87.8","article-title":"Correlation between vancomycin clearance and cystatin C-based glomerular filtration rate in paediatric patients.","volume":"87","author":"Oh","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"zoi230639r32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-20","article-title":"Prediction of vancomycin levels using cystatin C in overweight and obese patients: a retrospective cohort study of hospitalized patients.","volume":"65","author":"Teaford","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"zoi230639r33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2016.11.016","article-title":"Cystatin C-guided vancomycin dosing in critically ill patients: a quality improvement project.","volume":"69","author":"Frazee","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi230639r34","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/cc13899","article-title":"Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.","volume":"18","author":"Frazee","year":"2014","journal-title":"Crit Care"},{"issue":"3","key":"zoi230639r35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.mayocp.2018.08.002","article-title":"Prediction of the renal elimination of drugs with cystatin C vs creatinine: a systematic review.","volume":"94","author":"Barreto","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"zoi230639r36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7326\/0003-4819-124-3-199602010-00006","article-title":"Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.","volume":"124","author":"Alappan","year":"1996","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi230639r37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/2000-1967-087","article-title":"Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment.","volume":"109","author":"Hallberg","year":"2004","journal-title":"Ups J Med Sci"},{"issue":"3","key":"zoi230639r38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7150\/ijms.3.92","article-title":"Serum cystatin C levels to predict serum concentration of digoxin in Japanese patients.","volume":"3","author":"Nakamura","year":"2006","journal-title":"Int J Med Sci"},{"issue":"4","key":"zoi230639r39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1046\/j.1365-2125.2002.01549.x","article-title":"Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine.","volume":"53","author":"O\u2019Riordan","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"zoi230639r40","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1177\/0091270007305503","article-title":"Estimation of the glomerular filtration rate from serum creatinine and cystatin C with regard to therapeutic digoxin monitoring.","volume":"47","author":"Garcia","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"zoi230639r41","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.v34.10","article-title":"Cystatin C may be better than creatinine for digoxin dosing in older adults with atrial fibrillation.","volume":"34","author":"\u0160\u00e1lek","year":"2020","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"zoi230639r42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/emm.2006.18.issue-1","article-title":"Baclofen overdose: defining the spectrum of toxicity.","volume":"18","author":"Leung","year":"2006","journal-title":"Emerg Med Australas"},{"issue":"4","key":"zoi230639r43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.kint.2020.05.026","article-title":"Back off baclofen when the kidneys don\u2019t work.","volume":"98","author":"Norouzi","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"zoi230639r44","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/hep.26556","article-title":"Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis.","volume":"59","author":"Mindikoglu","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"zoi230639r45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10620-017-4897-z","article-title":"Cystatin C is a gender-neutral glomerular filtration rate biomarker in patients with cirrhosis.","volume":"63","author":"Mindikoglu","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"11","key":"zoi230639r46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2337\/dc11-2220","article-title":"Serum concentration of cystatin C and risk of end-stage renal disease in diabetes.","volume":"35","author":"Krolewski","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi230639r47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1681\/ASN.2005050545","article-title":"Cystatin C and mortality risk in the elderly: the health, aging, and body composition study.","volume":"17","author":"Shlipak","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"zoi230639r48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/CIRCULATIONAHA.106.644286","article-title":"Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.","volume":"115","author":"Ix","year":"2007","journal-title":"Circulation"},{"key":"zoi230639r49","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/127943","article-title":"Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease.","volume":"2014","author":"Vigil","year":"2014","journal-title":"Int J Nephrol"},{"issue":"1","key":"zoi230639r50","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1038\/s41598-021-85370-8","article-title":"Cystatin C predicts long term mortality better than creatinine in a nationwide study of intensive care patients.","volume":"11","author":"Helmersson-Karlqvist","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"zoi230639r51","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/ndt\/gfp196","article-title":"Cystatin C is correlated with mortality in patients with and without acute kidney injury.","volume":"24","author":"Bell","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"zoi230639r52","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000128","article-title":"Accuracy of GFR estimating equations in patients with discordances between creatinine and cystatin C-based estimations.","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"zoi230639r53","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1053\/j.ajkd.2022.05.011","article-title":"Association of intra-individual differences in estimated GFR by creatinine versus cystatin C with incident heart failure.","volume":"80","author":"Chen","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"zoi230639r54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48940","article-title":"Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin C and end-stage kidney disease and mortality.","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi230639r55","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.ajkd.2020.05.017","article-title":"The difference between cystatin C- and creatinine-based estimated GFR and associations with frailty and adverse outcomes: a cohort analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).","volume":"76","author":"Potok","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"zoi230639r56","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1053\/j.ajkd.2020.05.018","article-title":"The difference between cystatin C- and creatinine-based estimated GFR and incident frailty: an analysis of the Cardiovascular Health Study (CHS).","volume":"76","author":"Potok","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"zoi230639r57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.plabm.2017.05.005","article-title":"Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients.","volume":"8","author":"Jones","year":"2017","journal-title":"Pract Lab Med"},{"issue":"2","key":"zoi230639r58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clinbiochem.2005.10.009","article-title":"Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia.","volume":"39","author":"Demirtas","year":"2006","journal-title":"Clin Biochem"},{"issue":"7","key":"zoi230639r59","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3109\/0886022X.2014.918813","article-title":"Correlation of cystatin-C and radionuclidic measurement method of glomerular filtration rate in patients with lung cancer receiving cisplatin treatment.","volume":"36","author":"Oc","year":"2014","journal-title":"Ren Fail"},{"issue":"2","key":"zoi230639r60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing.","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"zoi230639r61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/599188","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi230639r62","first-page":"39","article-title":"Mortalidad inmediata y a los 30 d\u00edas en las intoxicaciones digit\u00e1licas atendidas en servicios de urgencias de Catalu\u00f1a.","volume":"31","author":"Superv\u00eda Caparr\u00f3s","year":"2019","journal-title":"Emergencias"},{"issue":"12","key":"zoi230639r63","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jamadermatol.2022.3541","article-title":"Risk factors for vancomycin drug reaction with eosinophilia and systemic symptoms syndrome.","volume":"158","author":"Blumenthal","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806843\/hanna_2023_oi_230639_1687873091.88265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:03:53Z","timestamp":1688555033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.21715","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}